Tīmeklis2024. gada 25. jūl. · Introduction Patients with relapsed or refractory multiple myeloma (RRMM) represent an unmet clinical need. Belantamab mafodotin (belamaf; … Tīmeklis2024. gada 11. maijs · Belantamab mafodotin (belamaf), an antibody-drug conjugate approved for the treatment of relapsed and refractory multiple myeloma (RRMM), is …
Management of belantamab mafodotin-associated corneal …
Tīmeklis2024. gada 7. sept. · The recommended dose reduction for adverse reactions is: 1.9 mg/kg IV once every 3 weeks; discontinue therapy in patients who are unable to … Tīmeklis2024. gada 5. nov. · Belantamab mafodotin is an antibody drug conjugate targeting B-cell maturation antigen (BCMA) on plasma cells and was the first BCMA-targeted … lam histology
Exploring Alternative Dosing Regimens of Single-Agent Belantamab ...
TīmeklisTo examine the ocular AEs associated with single-agent belantamab mafodotin in DREAMM-14 using alternative dosing regimens in Arms B to D compared to Arm A Incidence rate of Grade ≥2 ocular AEs according to a modified keratopathy and visual acuity (KVA) scale Secondary objectives and endpoints To further evaluate ocular … TīmeklisBelantamab mafodotin Malignant Plasma Cell BCMA Effector Cell ADC ADCC/ADCP Lysosome BCMA Fc Receptor Cell Death ... (KVA) scale and CTCAE. CO-6 Ocular AEs Well Understood by Ophthalmologists Tīmeklis2024. gada 15. marts · Belantamab mafodotin will be administered as a combination therapy as a calculated dose on Day 1 of every other 28-day cycle. Belantamab mafodotin starting dose: ... Number of participants with ocular toxicity of Grade 2 or higher (per KVA scale). Part 2: Overall Response Rate (ORR) [ Time Frame: Up to 4 … lamh learning